Key result
Lipid-lowering therapy linked to a ~37% improvement in myocardial vasodilatation in hypercholesterolemic patients.
Why the study?
Whether diminished myocardial vasodilatation of angiographically normal coronary arteries in hypercholesterolemics can be reversed after lipid-lowering therapy was not known.
Does lipid-lowering therapy improve impaired myocardial vasodilatation in hypercholesterolemic patients with anatomically normal coronary arteries?
Cohort (n=43)
Does lipid-lowering therapy improve impaired myocardial vasodilatation in hypercholesterolemic patients with anatomically normal coronary arteries?
Absolute Event Rate: 2.77% vs 2.02%
p-value: p=<0.05
Lipid-lowering therapy can reverse diminished myocardial vasodilatation in anatomically normal coronary arteries of hypercholesterolemic patients.
No takes yet. Share an insight, caveat, or question.
Lipid-lowering may improve MVD in hypercholesterolemics with normal coronaries; leaves open clinical benefit and requires randomized confirmation.
Yokoyama et al. (1999) conducted a cohort in Hypercholesterolemia (n=43). Lipid-lowering therapy vs. Before treatment and age-matched controls was evaluated on Myocardial vasodilatation (MVD) (p=<0.05). Lipid-lowering therapy significantly improved myocardial vasodilatation in hypercholesterolemic patients from 2.02 to 2.77 (P<0.05), though it remained lower than in healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: